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Summary
Background Health care for people living with HIV has improved substantially in the past two decades. Robust 
estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to 
patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients 
starting combination antiretroviral therapy (ART) between 1996 and 2013.
Methods We analysed data from 18 European and North American HIV-1 cohorts. Patients (aged ≥16 years) were 
eligible for this analysis if they had started ART with three or more drugs between 1996 and 2010 and had at least 
3 years of potential follow-up. We estimated adjusted (for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA 
at start of ART) all-cause and cause-specific mortality hazard ratios (HRs) for the first year after ART initiation and the 
second and third years after ART initiation in four calendar periods (1996–99, 2000–03 [comparator], 2004–07, 
2008–10). We estimated life expectancy by calendar period of initiation of ART.
Findings 88 504 patients were included in our analyses, of whom 2106 died during the first year of ART and 2302 died 
during the second or third year of ART. Patients starting ART in 2008–10 had lower all-cause mortality in the first year 
after ART initiation than did patients starting ART in 2000–03 (adjusted HR 0·71, 95% CI 0·61–0·83). All-cause 
mortality in the second and third years after initiation of ART was also lower in patients who started ART in 2008–10 
than in those who started in 2000–03 (0·57, 0·49–0·67); this decrease was not fully explained by viral load and CD4 cell 
count at 1 year. Rates of non-AIDS deaths were lower in patients who started ART in 2008–10 (vs 2000–03) in the 
first year (0·48, 0·34–0·67) and second and third years (0·29, 0·21–0·40) after initiation of ART. Between 1996 and 2010, 
life expectancy in 20-year-old patients starting ART increased by about 9 years in women and 10 years in men.
Interpretation Even in the late ART era, survival during the first 3 years of ART continues to improve, which probably 
reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of 
comorbidity. Prognostic models and life expectancy estimates should be updated to account for these improvements.
Funding UK Medical Research Council, UK Department for International Development, EU EDCTP2 programme.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
For 20 years, combination antiretroviral therapy (ART) has 
been the standard approach to treating HIV-1 infection in 
Europe and North America. The first ART regimens were 
inferior to those currently available, which better suppress 
HIV replication, are less toxic, and have higher genetic 
barriers to resistance, reduced pill burden (often one a 
day), and fewer side-effects.1,2 Other improvements in 
health care since 1996 for people living with HIV include 
treatment and prophylaxis for opportunistic infections 
and management of co morbidities.3 Improvements in 
intensive care manage ment, disease screening, and health 
promotion might also have improved prognosis. Therefore, 
people living with HIV who started ART more recently 
might have improved survival compared with those treated 
earlier in the ART era.
The Antiretroviral Therapy Cohort Collaboration 
(ART-CC) previously reported that despite improvements 
in virological response to ART, mortality 1 year after 
initiation of ART did not decrease between 1998 and 2003.4 
This absence of improvement in survival might have 
been related to changes in patients’ characteristics: 
increasing numbers were from areas with a high 
prevalence of tuberculosis infection.4 Some studies have 
reported improvements in overall survival and changing 
causes of death, with proportionately fewer AIDS-related 
deaths in more recent years,5–9 but none has investigated 
trends in prognosis after starting ART by calendar period. 
We examined changes in all-cause and cause-specific 
mortality in the first 3 years of ART during 1996–2013, 
and investigated trends in life expectancy.
Methods
Participants
We combined data from 18 European and North American 
HIV cohorts participating in ART-CC, which includes 
ART-naive people living with HIV aged 16 years or older 
who started treatment with three or more antiretroviral 
For more on ART-CC see 
http://www.bristol.ac.uk/art-cc
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drugs between 1996 and 2010.10 Cohorts were approved 
by ethics committees or institutional review boards, used 
standardised data collection methods, and scheduled 
follow-up visits at least every 6 months. Cohorts included 
in this paper were the French Hospital Database on HIV 
(FHDH); the Italian Cohort of Antiretroviral-naive patients 
(ICONA); the Swiss HIV Cohort Study (SHCS); the AIDS 
Therapy Evaluation project, Netherlands (ATHENA); the 
Multicenter Study Group on EuroSIDA; the Aquitaine 
Cohort, France; the Royal Free Hospital Cohort, UK; the 
South Alberta Clinic Cohort, Canada; the Danish HIV 
Cohort Study, Denmark; HAART Observational Medical 
Evaluation and Research (HOMER) Cohort, Canada; 
HIV Atlanta Veterans Affairs Cohort Study (HAVACS), 
USA; Osterreichische HIV-Kohortenstudie (OEHIVKOS), 
Austria; Proyecto para la Informatizacion del Seguimiento 
Clinico-epidemiologico de la Infeccion por HIV y SIDA 
(PISCIS), Spain; University of Washington HIV Cohort, 
USA; VACH, Spain; Veterans Aging Cohort Study (VACS), 
USA; Vanderbilt, USA; and the Koln/Bonn Cohort, 
Germany.
Eligible patients started ART at least 3 years before 
the cohort-specific database close date, which varied 
from May 31, 2012, to July 31, 2013, and had a baseline 
CD4 cell count measured within a window 3 months 
before until 2 weeks after starting ART. We defined 
CD4 cell count and viral load 1 year after the start of 
ART as the closest measurement before 1 year within 
a 9–12 month window.
Patients were followed up for all-cause and cause-specific 
mortality from the time of starting ART, considered lost 
to follow-up if there was a gap of more than 1 year 
between the dates they were last known to be alive and 
the database close date, and censored 6 months after the 
last recorded measurement. Mortality infor mation was 
obtained through linkage with Vital Statistics agencies and 
hospitals or physician report and active follow-up of 
participants. Methods for classifying causes of death, with 
an adaptation of the CoDe project protocol, are described 
elsewhere.11 Deaths were coded as AIDS-related if there 
was a serious AIDS defining condition close to death or a 
low CD4 cell count (<100 cells per µL) before death, and 
a diagnosis compatible with AIDS as cause of death.
Statistical analysis
We compared characteristics of patients by calendar 
period of initiation of ART (1996–99, 2000–03, 2004–07, 
2008–10). We used Cox models stratified by cohort to 
estimate unadjusted and adjusted mortality hazard 
ratios (HRs) by period of initiation of ART. Models were 
adjusted for sex, injecting drug use, AIDS at baseline, 
age (16–29, 30–39, 40–49, 50–59, ≥60 years), CD4 cell 
count (0–24, 25–49, 50–99, 100–199, 200–349, 350–499, 
≥500 cells per µL), and HIV-1 RNA viral load (0 to 
<10 000, ≥10 000 to <100 000, ≥100 000 copies per mL) at 
the start of ART. Because mortality is higher in the first 
year of ART, we fitted separate models for the first year 
after starting ART and the second and third years after 
Research in context
Evidence before this study
We ran three PubMed searches for articles published between 
Jan 1, 2001, and June 1, 2016, with the terms (1) “HIV”, “calendar 
year”, and “mortality”; (2) “HIV”, “life expectancy”, and 
“mortality”; (3) “HIV”, “causes of death”, and “mortality”. A study 
of 2675 patients in the Australian HIV cohort found lower 
mortality in individuals who started antiretroviral therapy (ART) 
from 2004 onwards compared with earlier years, although that 
study focused on the effect of duration of treatment rather than 
trends in early mortality on ART. A large study by D:A:D found 
lower all-cause, cardiovascular, and liver disease mortality in 
patients followed up in 2009–11 compared with 1999–2000, 
but did not analyse deaths by period of starting ART. We 
previously reported that between 1995 and 2003, virological 
response to ART improved but early mortality did not decrease. 
Surveillance data from the USA showed increasing life 
expectancy with year of HIV diagnosis between 1996 and 2005. 
We also reported that life expectancy in individuals starting ART 
increased between 1996 and 2005; studies in Europe and 
the USA have also shown increases in life expectancy over time.
Added value of this study
Our study, based on a large collaboration of cohorts in Europe 
and North America, found that substantial declines in 
mortality for individuals starting ART in 2008–10, compared 
with earlier years, has resulted in increased life expectancy. 
However, this life expectancy remains lower than that of the 
general population. Declines in mortality were greater for the 
second and third years after starting ART than for the 
first year after starting ART. Rates of non-AIDS-related deaths, 
particularly deaths from cardiovascular disease, were 
substantially lower in 2008–10 than previously. There was 
little evidence that mortality has declined in people who 
inject drugs.
Implications of all the available evidence
Improvements in the care of people living with HIV since the 
introduction of ART 20 years ago have led to improved 
survival and increased life expectancy in those starting ART. 
These improvements probably reflect the availability of 
superior antiretroviral agents, more options for the 
management of patients developing resistance, fewer drug 
interactions, better management of opportunistic infections 
and chronic diseases, and introduction of screening and 
prevention programmes. Prognostic models and estimates of 
life expectancy should be updated to account for these 
improvements.
For the CoDe project see 
http://www.chip.dk/Tools-
Standards/CoDe/About
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starting ART. To investigate the mediating effect of 
response to therapy, we additionally adjusted the second 
and third year analysis for CD4 cell count and viral load 
measured 1 year after initiation of ART. We compared 
HR for regimen failure, defined as switching regimen 
within 6 months of a viral load measurement of more 
than 1000 copies per mL after first achieving viral 
suppression, by period of ART initiation. In patients 
with regimen failure, we estimated mortality HR by 
period of ART initiation.
We used Cox models to investigate the consistency of 
mortality trends across subgroups of patients defined by 
sex and transmission risk (men who have sex with men 
[MSM], male heterosexual, female heterosexual, men 
who inject drugs, women who inject drugs) in European 
patients (because transmission risk was missing for 
large numbers of North American patients); CD4 cell 
count categories (<100, 100–199, 200–349, ≥350 cells 
per µL); age; and region (Europe, North America). In a 
sensitivity analysis, patients were considered lost to 
follow-up at 6 months rather than 12 months. We 
repeated analyses with the following causes of death 
as the outcome: AIDS-related, non-AIDS-related (ie, 
non-AIDS infection, malignancies not caused by AIDS 
or hepatitis, liver disease, cardiovascular disease, and 
other [causes with ≤20 cases]), and unnatural causes 
(suicide, accident or other violent death, euthanasia, and 
substance abuse), and those missing or unknown. We 
estimated sex-specific life expectancy by period of ART 
initiation, overall and by region (North America, Europe). 
We used a Poisson model to estimate mortality in age 
bands of 5 years, which were used to construct life tables 
and estimate average age at death for those aged 20 years 
at initiation of ART. We compared these estimates with 
those from the French and US general populations. For 
comparability across periods and to investigate the effect 
of higher mortality in the first year of ART, we estimated 
life expectancy on the basis of mortality in the first 3 years 
of follow-up, and then with mortality in the second and 
third years of follow-up. Because there were few patients 
aged 70 years or older, for the oldest open-ended age 
group we used the French general population mortality 
multiplied by the mean rate ratio in ART-CC compared 
with the French general population (chosen because 
France contributed the most patients) for ages 60–64 and 
65–69 years. Per-period changes in life expectancy 
were estimated with metaregression. We used Stata 
(version 14) for analyses.
Role of the funding source
The funders of the study, the UK Medical Research 
Council, UK Department for International Development, 
and the European Union, had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results
88 504 patients were eligible for our analyses. During 
84 621 person-years, 2106 (2%) patients died in the first year 
after starting ART (24·9 per 1000 person-years). 81 608 (92%) 
individuals remained in the study for more than 1 year, of 
whom 2302 (3%) died during 153 813 person-years (15·0 per 
1000 person-years). 4594 (5%) patients were lost to follow-up 
during the first year after starting ART and 6674 patients 
(8%) were lost-to follow-up during the second and third 
years. Patients who were lost to follow-up had lower viral 
loads and higher CD4 cell counts than were those not lost to 
follow-up, and they were also more likely to be female, 
younger, and people who inject drugs (data not shown).
The proportion of women increased from 20% in 
1996–99 to 28% in 2004–07, then decreased to 21% 
in 2008–10 (table 1). Median age increased between 
1996–99 2000–03 2004–07 2008–10
Total deaths 1431/24 445 (6%) 1452/25 683 (6%) 1084/24 462 (4%) 441/13 914 (3%)
Men 1240/19 529 (6%) 1231/18 653 (7%) 882/17 570 (5%) 377/10 995 (3%)
Women 191/4916 (4%) 221/7030 (3%) 202/6892 (3%) 64/2919 (2%)
No injecting drug use 1161/20 186 (6%) 1187/22 182 (5%) 877/22 020 (4%) 385/12 885 (3%)
Injecting drug use 270/4259 (6%) 265/3501 (8%) 207/2442 (8%) 56/1029 (5%)
No AIDS 810/19 118 (4%) 799/19 589 (4%) 595/19 262 (3%) 239/11 570 (2%)
AIDS 621/5327 (12%) 653/6094 (11%) 489/5200 (9%) 202/2344 (9%)
Age (years) 36 (31–43) 37 (31–45) 39 (32–46) 40 (32–47)
16–29 117/4457 (3%) 95/4620 (2%) 55/4118 (1%) 23/2208 (1%)
30–39 508/11 176 (5%) 399/10 320 (4%) 256/8846 (3%) 74/4651 (2%)
40–49 433/5729 (8%) 485/6714 (7%) 352/7294 (5%) 142/4311 (3%)
50–59 257/2270 (11%) 313/2998 (10%) 261/3003 (9%) 115/1919 (6%)
≥60 116/813 (14%) 160/1031 (16%) 160/1201 (13%) 87/825 (11%)
CD4 count (cells per µL) 238 (93–394) 200 (81–326) 219 (115–310) 265 (157–351)
0–24 356/2511 (14%) 355/2789 (13%) 232/1921 (12%) 97/849 (11%)
25–49 173/1508 (11%) 179/1753 (10%) 102/1291 (8%) 37/559 (7%)
50–99 197/2332 (8%) 244/2771 (9%) 173/2203 (8%) 57/891 (6%)
100–199 288/4212 (7%) 331/5461 (6%) 246/5370 (5%) 69/2272 (3%)
200–349 237/6171 (4%) 217/7354 (3%) 240/9090 (3%) 115/5764 (2%)
350–499 109/4258 (3%) 76/3171 (2%) 58/2673 (2%) 44/2384 (2%)
≥500 71/3453 (2%) 50/2384 (2%) 33/1914 (2%) 22/1195 (2%)
HIV-1 RNA 
(log copies per mL)
4·9 (4·2–5·4) 4·9 (4·3–5·4) 4·8 (4·1–5·3) 4·7 (4·1–5·2)
0–3·99 177/4439 (4%) 179/4693 (4%) 132/5317 (2%) 70/3224 (2%)
4–4·99 396/9397 (4%) 426/9355 (5%) 332/8937 (4%) 158/5675 (3%)
≥5 858/10 609 (8%) 847/11 635 (7%) 620/10 208 (6%) 213/5015 (4%)
Regimen
NNRTI-based 210/4178 (5%) 609/11 391 (5%) 460/12 126 (4%) 215/7902 (3%)
Protease 
inhibitor-based
1159/19 184 (6%) 602/9520 (6%) 555/10 496 (5%) 197/5398 (4%)
NRTI/abacavir* 18/364 (5%) 196/4040 (5%) 47/1312 (4%) 4/117 (3%)
NRTI/non-abacavir† 28/542 (5%) 29/564 (5%) 6/240 (3%) 0/29 (0%)
Other 16/177 (9%) 16/168 (10%) 16/288 (6%) 25/468 (5%)
Data are number of deaths/number of patients (%) or median (IQR). NNRTI=non-nucleoside reverse transcriptase inhibitor. 
NRTI=nucleoside reverse transcriptase inhibitor. *Triple NRTI including abacavir. †Triple NRTI not including abacavir.
Table 1: Characteristics of patients at the time of starting antiretroviral therapy with number of deaths, 
by period of initiation
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1996–99 and 2008–10, whereas the proportion of people 
who inject drugs decreased from 17% to 7%. Median 
CD4 count 1 year after ART initiation increased 
substantially, from 370 cells per µL (IQR 211–572) in 
1996–99 to 430 cells per µL (295–570) in 2008–10, and the 
proportion of patients with HIV-1 RNA viral load of 
500 copies per mL or lower increased from 71% in 
1996–99 to 93% in 2008–10.
During 1996–99, most patients started a protease 
inhibitor-based regimen, whereas after 2000 non-
nucleoside reverse transcriptase inhibitor (NNRTI)-
based regimens were most common (table 2). The 
protease inhibitors indinavir, nelfinavir, and saquinavir 
were replaced by atazanavir, darunavir, and lopinavir. Of 
the NNRTIs, efavirenz was the most commonly used 
third regimen drug from 2000 onwards. The NRTIs 
didanosine, stavudine, and zidovudine were replaced by 
abacavir and tenofovir.
Compared with patients who started ART in 2000–03, 
all-cause mortality during the first year of ART was 
similar in patients who started ART between 1996 
and 2007, but substantially lower for those who started 
ART in 2008–10 (adjusted HR 0·71, 95% CI 0·61–0·83; 
figure 1). The adjusted HR per calendar period was 0·90 
(0·87–0·95). Declines in 1 year mortality over calendar 
time were consistent across subgroups of patients defined 
by their characteristics at the start of ART, apart from 
individuals who inject drugs and those starting ART with 
CD4 counts less than 100 cells per µL or CD4 count 
greater than or equal to 350 cells per µL (appendix).
All-cause mortality in the second and third years 
after starting ART declined substantially over calendar 
time (adjusted HR per calendar period 0·78, 95% CI 
0·75–0·82; figure 2). Declines were consistent across 
Europe and North America, age groups, and CD4 cell 
count at ART initiation. The decline in mortality was 
less in people who inject drugs (adjusted HR per 
calendar period 0·90 [0·80–1·02] for men and 0·95 
[0·76–1·20] for women; appendix p 1) than in other 
groups. We examined the mediating effects of CD4 cell 
count and viral load measured 1 year after starting ART 
on mortality trends during the second and third years of 
ART in 53 244 (65%) eligible patients with available 
measurements (figure 2). Additionally adjusting for 
1 year CD4 cell count and viral load attenuated the 
adjusted HR per calendar period to 0·90 (0·85–0·96). 
The proportion of patients with regimen failure declined 
over time (adjusted HR per calendar period 0·73, 
0·72–0·75), but among those with regimen failure there 
was no evidence of an improvement in survival (adjusted 
HR per calendar period 0·98, 0·87–1·09; appendix p 2). 
Results of sensitivity analyses in which patients were 
considered lost to follow-up at 6 months rather than 
12 months were similar to the main analyses (data 
not shown).
Figure 1: Unadjusted and adjusted all-cause mortality hazard ratios for the 
first year after starting antiretroviral therapy (ART), by period of initiation
*Adjusted for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at the 
time of starting ART.
Adjusted*
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(n=24 445)
2000–03 
(n=25 683)
2004–07 
(n=24 462)
2008–10 
(n=13 914)
Protease inhibitors
Amprenavir 0 1% 0 0
Atazanavir 0 0 13% 19%
Darunavir 0 0 0 3%
Fosamprenavir 0 0 6% 2%
Indinavir 37% 9% 1% 0
Lopinavir 0 8% 16% 13%
Nelfinavir 25% 16% 3% 0
Ritonavir 7% 1% 1% 2%
Saquinavir 10% 3% 3% 1%
Non-nucleoside reverse transcriptase inhibitors
Efavirenz 6% 30% 42% 50%
Nevirapine 12% 15% 8% 7%
Entry inhibitors
Enfuvirtide 0 0 1% 0
Integrase inhibitors
Raltegravir 0 0 0 3%
Nucleoside reverse transcriptase inhibitors
Abacavir 2% 18% 16% 11%
Didanosine 17% 14% 7% 1%
Emtricitabine 0 0 37% 80%
Lamivudine 80% 90% 59% 19%
Stavudine 40% 20% 2% 0
Tenofovir 0 5% 49% 79%
Zalcitabine 3% 0 0 0
Zidovudine 59% 68% 34% 8%
Table 2: Proportion of patients prescribed specific antiretroviral drugs as 
their first regimen, by period of initiation
See Online for appendix
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Causes were classified for 3126 (71%) of 4408 deaths. 
Rates of deaths from AIDS during the first year of ART 
declined over calendar time (adjusted HR per calendar 
period 0·93, 95% CI 0·86–0·99), with greater declines 
for the second and third year of ART (0·69, 0·64–0·76). 
Rates of non-AIDS-related death during the first year of 
follow-up declined over calendar time (0·87, 0·80–0·95), 
as did rates during the second and third years of follow-up 
(0·75, 0·69–0·81). Declines in mortality were consistent 
across causes of mortality (table 3): the greatest decline 
was in liver-related deaths during the second and third 
years of ART.
Life expectancy increased with calendar period of 
initiation of ART, for both men and women (figure 3 
and appendix p 2). Expected average ages at death for 
Europeans aged 20 years starting ART in 2008–10, on 
the basis of mortality during the first 3 years of ART, 
were 67·6 years (95% CI 66·7–68·5) for men and 
67·9 years (67·2–68·7) for women, lower than in the 
French general population (79 years in men and 85 years 
in women). Life expectancy was lower in North America 
(expected age at death 65·9 years [65·0–66·8] in men 
and 63·2 years [62·2–64·3] in women for patients aged 
20 years starting ART in 2008–10) than in Europe and 
was lower than in the US general population (78 years in 
men and 82 years in women). When estimates of life 
expectancy were based on mortality during the second 
and third years of ART, the average ages at death were 
around 10 years higher. Increases in life expectancy over 
calendar time were similar when estimated with data for 
the first 3 years and for the second and third years of 
follow-up. The expected age at death of a 20-year-old 
patient starting ART during 2008–10, who had a 
CD4 count of more than 350 cells per µL 1 year after 
starting ART, was 78·0 years (77·7–78·3).
Discussion
Between 1996 and 2013, survival of people living with 
HIV in the first 3 years since ART initiation improved 
substantially. During the first year of ART, mortality was 
similar in patients who started ART between 1996 
and 2007, but lower during 2008–10. Survival over 
calendar time improved consistently during the second 
and third years after initiation of ART. Declines in 
mortality were lower in people who inject drugs than in 
other groups. Response to ART, measured by CD4 cell 
count and viral load 1 year after starting ART, only partly 
explained improvements in survival during the second 
and third years of ART. AIDS-related and non-AIDS-
related mortality declined over calendar time, during the 
first year and second–third years after ART initiation. 
Life expectancy in patients starting ART has increased by 
about 10 years during the ART era, but remains lower 
than in the general population. Patients who started ART 
during 2008–10 whose CD4 counts exceeded 350 cells 
per µL 1 year after ART initiation have estimated life 
expectancy approaching that of the general population.
Reduced mortality during the first year of ART is likely 
to be explained by better initial regimens with greater 
effectiveness and improved tolerability with fewer 
side-effects, because rates of regimen modification are 
highest soon after starting ART.12 Improvements in 
survival during the second and third years of ART are 
probably caused by increased viral suppression, declining 
rates of viral failure, and increasing treatment options.13,14 
Simpler regimens might have contributed to improve-
ments in both short-term and long-term adherence 
to ART. Drug pharmacokinetics have improved and 
since 2006, single daily pill formulations with fewer drug 
interactions have been available.2 Mortality soon after 
starting ART is strongly influenced by the proportion of 
patients who start ART with severe immunodeficiency 
(late presentation), but reductions in the proportion of 
such patients starting ART do not explain our findings, 
because we controlled for previous AIDS and for CD4 cell 
count at ART initiation. Better management of patients 
with late presentation of HIV infection and more general 
improvements in health care for people living with HIV 
Figure 2: All-cause mortality hazard ratios for the second and third years 
after starting antiretroviral therapy (ART), by period of initiation
*Adjusted for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at the 
time of starting ART.
Additionally adjusted for CD4 cell count and viral load at 1 year
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could have contributed to improved survival. With the 
perception that HIV-positive people will live into old age, 
clinicians are screening for and treating comorbidities 
more aggressively, including common disorders such as 
cardiovascular disease, hepatitis C, and cancer. Increasing 
life expectancy might encourage patients to engage in 
risk reduction programmes, to cease smoking, and to 
increase adherence to ART.15 In the USA, improved 
survival after 2010 could in part be a result of the 
introduction of the National HIV/AIDS Strategy, which 
aimed to increase access to care, improve health 
outcomes, and address health inequities among people 
living with HIV.
Rates of AIDS deaths during the first year of ART were 
substantially lower in the most recent period, which is 
probably caused by declining rates of more serious AIDS 
events, such as AIDS-defining malignancies.6 As we 
reported previously,16 the proportion of deaths from 
AIDS has declined over time. The substantial decline in 
cardiovascular mortality could be a result of more 
aggressive screening and treatment of cardiovascular 
risk factors, decreasing contraindications for lipid-
lowering medications, especially statins (because of 
drug interactions or poor overall condition), and reduced 
use of abacavir in individuals who have high viral loads, 
are HLA B5701 positive or are at high risk of myocardial 
infarction.17 Moreover, the incidence of cardiovascular 
disease has decreased in the general population over 
time, and therapeutic interventions have improved.18
Between 1996–99 and 2008–10, life expectancy in 
people living with HIV starting ART increased by around 
Number of deaths Period of ART initiation Per period
1996–99 2000–03 2004–07 2008–10
First year of follow-up
AIDS 902 0·98 (0·83–1·16) 1 0·94 (0·79–1·11) 0·71 (0·56–0·90) 0·93 (0·86–0·99)
Non-AIDs 525 1·04 (0·83–1·30) 1 1·09 (0·88–1·35) 0·48 (0·34–0·67) 0·87 (0·80–0·95)
Non-AIDS infection 117 0·89 (0·55–1·43) 1 1·11 (0·71–1·74) 0·45 (0·22–0·94) 0·91 (0·76–1·10)
Non-AIDS, non-hepatitis 
malignancies
122 1·01 (0·61–1·68) 1 1·53 (0·97–2·39) 0·65 (0·34–1·24) 0·99 (0·83–1·18)
Liver-related 76 1·07 (0·60–1·88) 1 0·93 (0·52–1·67) 0·36 (0·14–0·96) 0·80 (0·63–1·01)
Cardiovascular 64 0·95 (0·52–1·73) 1 0·72 (0·39–1·35) 0·19 (0·06–0·62) 0·71 (0·55–0·92)
Other 146 1·18 (0·78–1·78) 1 1·03 (0·67–1·59) 0·64 (0·34–1·19) 0·87 (0·73–1·02)
Unnatural* 107 1·37 (0·82–2·29) 1 1·49 (0·90–2·48) 0·62 (0·29–1·34) 0·89 (0·73–1·08)
Missing/unknown 572 1·00 (0·81–1·24) 1 0·86 (0·69–1·08) 0·98 (0·76–1·23) 0·97 (0·89–1·05)
Second and third years of follow-up
AIDS 646 1·34 (1·12–1·60) 1 0·74 (0·59–0·92) 0·35 (0·24–0·51) 0·69 (0·64–0·76)
Non-AIDS 770 1·12 (0·94–1·34) 1 0·86 (0·71–1·03) 0·29 (0·21–0·40) 0·75 (0·69–0·81)
Non-AIDS infection 132 0·79 (0·52–1·19) 1 0·66 (0·43–1·04) 0·27 (0·12–0·59) 0·79 (0·66–0·95)
Non-AIDS, non-hepatitis 
malignancies
206 1·48 (1·03–2·13) 1 1·40 (0·97–2·00) 0·50 (0·28–0·87) 0·82 (0·71–0·94)
Liver-related 127 0·94 (0·63–1·40) 1 0·49 (0·30–0·79) 0·15 (0·05–0·42) 0·66 (0·54–0·80)
Cardiovascular 100 0·82 (0·50–1·34) 1 0·79 (0·49–1·29) 0·21 (0·08–0·53) 0·78 (0·64–0·95)
Other 205 1·47 (1·05–2·05) 1 0·93 (0·64–1·34) 0·29 (0·14–0·59) 0·69 (0·60–0·80)
Unnatural* 176 1·06 (0·74–1·53) 1 0·91 (0·62–1·35) 0·32 (0·16–0·63) 0·79 (0·68–0·92)
Missing/unknown 710 1·23 (1·02–1·48) 1 0·73 (0·58–0·91) 1·19 (0·96–1·49) 0·93 (0·87–1·00)
Data are hazard ratio (95% CI), mutually adjusted for age, sex, AIDS, risk group, CD4 cell count, HIV-1 RNA, and stratified by cohort, with 2000–03 as comparator. *Unnatural 
deaths include suicide, accident or other violent death, euthanasia, and substance abuse.
Table 3: Adjusted hazard ratios for specific causes of death by period of antiretroviral therapy (ART) initiation for first year of ART and second and 
third years of ART
Figure 3: Expected age at death of men and women living with HIV starting 
antiretroviral therapy (ART) aged 20 years, by period of initiation
Estimates of life expectancy were based on mortality during the first 3 years of 
follow-up and the second and third years of follow-up. Data are for all regions.
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10 years for both sexes, in Europe and North America. 
However, the 12-year improvements that we found were 
less than the 15–24 year increases over similar time 
periods reported by other studies in the UK and North 
America.19–22 Two of these studies examined trends by 
period of follow-up21,22 and two19,20 did not control for 
duration of ART, which tends to increase estimated life 
expectancy in earlier periods relative to later periods23 
because mortality is higher soon after the start of ART 
than after successful treatment for a number of years. 
Estimates of life expectancy in patients who survive the 
first year of ART are much higher than at ART initiation, 
reflecting the importance of starting therapy early in the 
course of HIV infection.20,23
We analysed data for many people living with HIV 
who were receiving routine clinical care in western 
Europe, the USA, and Canada. Some cohorts, such as 
the Danish HIV cohort, FHDH (France), and ATHENA 
(Netherlands) cover most of their countries. Others are 
regional but are representative of public care for the 
areas in which they operate. Therefore, our findings 
should be generalisable to treated people living with 
HIV in high-income settings. We compared patients 
with the same potential years of follow-up between 
calendar periods and accounted for heterogeneity in 
death rates between cohorts.24 Our results might be 
affected by confounding: patient characteristics have 
changed during the 20 years that ART has been 
available, with a smaller proportion of infections 
in people who inject drugs in more recent years and 
changing patterns of migration from sub-Saharan 
Africa. Transmission group is sometimes misclassified, 
and transmission for people who inject drugs does not 
necessarily imply continuing drug use. Outcomes in 
patients lost to follow-up within 3 years of starting ART 
are uncertain, but most cohorts link to death registries. 
CD4 cell count and viral load 1 year after starting ART 
were missing for some patients who might have been 
less engaged in care and likely to have worse prognosis. 
Mortality was estimated on pooled data and therefore 
the estimated life expectancy reflects patients’ average 
experience. Estimates of life expectancy are sensitive to 
mortality in the oldest age groups, for which data are 
sparse. Our study only includes patients who started 
ART, whereas most deaths in people with HIV infection 
occur in the untreated population.
Our study tracks the progress made in treating people 
living with HIV between 1996 and 2013. Monitoring 
survival can clarify when and how improvements were 
achieved, and provides a benchmark against which 
current or future interventions, such as treatment with 
integrase inhibitors, guidelines recommending earlier 
treatment, or limiting CD4 cell count and viral load 
monitoring in stable patients, can be measured. 
Prognostic information is important to patients, their 
relatives, and clinicians, and can be used to inform 
health-care planning at the individual, clinic, and 
government levels. Improvements in survival with 
better ART regimens could provide evidence to policy 
makers that modern palatable and effective treatments 
should continue to be used in preference to older 
antiretroviral drugs that are becoming available as 
cheaper generics. Information about life expectancy in 
people living with HIV and the knowledge that it could 
be approaching that of the general population is 
important to motivate at-risk individuals to test for HIV 
and convince those infected to start ART immediately, 
and might decrease stigmatisation of people living with 
HIV and help them to obtain insurance or employment.
Since modern ART is highly effective and has low 
toxicity, the excess mortality in people living with HIV 
is unlikely to be addressed by further development of 
antiretroviral drugs. Instead, lifestyle issues that affect 
adherence to ART and non-AIDS mortality, and diagnosis 
and treatment of comorbidities in people living with HIV 
will need to be addressed. Interventions are needed to 
promote modern therapy to vulnerable populations, such 
as people who inject drugs, who currently do not fully 
benefit from ART. Improved access to opioid substitution 
treatment programmes and direct acting antiviral drugs 
for hepatitis C virus co-infection should be a priority for 
this group.25
Continued efforts are required to address late diagnosis 
and presentation to care to decrease mortality soon after 
starting ART, and support lifelong adherence to ART. 
Treatment guidelines changed in 2015 after results of the 
START trial showed clear benefits of immediate versus 
deferred treatment.26 Most future patients diagnosed 
with HIV are likely to start ART immediately (both for 
their own health and to prevent transmission to others), 
but this will only result in improved survival if the 
problems of late HIV diagnosis and access to care are 
addressed.
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